NasdaqGS:ADPTLife Sciences
Assessing Adaptive Biotechnologies (ADPT) Valuation After New Pfizer Deals And Digital Biotechnologies Financing
Adaptive Biotechnologies (ADPT) is back in focus after announcing two non-exclusive collaborations with Pfizer on T-cell receptor discovery and immune data licensing, as well as a new Series A financing round for its Digital Biotechnologies subsidiary.
See our latest analysis for Adaptive Biotechnologies.
At a share price of $15.96, Adaptive Biotechnologies has seen a 30 day share price return of 7.40% and a 1 year total shareholder return of 138.56%. Recent collaborations and financing news...